Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson’s Disease in Canada

 Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson’s Disease in Canada

Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson’s Disease in Canada

Shots:

  • The launch of Onstryv follows its Health Canada approval received on Jan 15, 2019 as an add-on therapy to a levodopa regimen indicated to treat signs and symptoms of idiopathic Parkinson’s disease in patients with off episodes
  • Valeo Pharma has exclusive rights for Onstryv and is responsible for all regulatory, quality, commercialization and distribution activities in Canada under an agreement with Zambon signed on Apr’2017
  • Onstryv (marketed as Xadago in ROW) is an oral, selective & reversible MAO-B-inhibitor, available in Canadian pharmacies as 50mg & 100mg tablets

Click here to read full press release/ article | Ref: Business Wire | Image: LinkedIn

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post